You are here

  • Home
  • Archive
  • Volume 75, Issue 3
  • Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Citation Tools

Article menu
Original research
Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Salas C, Martín-López J, Martínez-Pozo A, et al
Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)
Journal of Clinical Pathology 2022;75:193-200.